ArticleChemistry & biodiversity2025
Antibacterial Essential Oils as Adjuvants to Inhibit Antibiotic Resistance in Multidrug-resistant Bacteria.
Article in Chemistry & biodiversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multimodal Topical Formulations Combining Synthetic Anti-Inflammatory Agents, Levofloxacin, and Plant Extracts for Veterinary Wound and Inflammation Care: In Vivo Efficacy.Veterinary sciences · 2026Article
- Electrospinning of Natural Polymeric Fibers with Essential Oils for the Control of Multidrug-Resistant Pathogens.Polymers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to contribute to the fight against the antibiotic resistance crisis, we used a dual-activity prospection strategy for natural product mixtures with antibiotic resistance modulating and antibacterial activities in the essential oils (EOs) of Artemisia ludoviciana, Lippia graveolens, and Cosmos bipinnatus against multidrug-resistant strains of Pseudomonas aeruginosa HIM-MR01, Staphylococcus aureus HIM-MR02, Enterococcus faecalis HIM-MR05, and Salmonella typhi HIM-MR06. The three EOs exerted antibacterial activity on the bacterial strains with minimum inhibitory concentrations (MICs) ranging from 0.1735 to 65.6263 µg/mL. When combined with antibiotics, the L. graveolens EO showed the highest resistance modulation for vancomycin (VA), nalidixic acid (NA), and chloramphenicol against S. aureus (MIC: 0.0347 µg/mL), E. faecalis (MIC: 0.0832 µg/mL), and P. aeruginosa (MIC: 0.0694 µg/mL). For the A. ludoviciana EO, resistance modulation was based on S. aureus-VA (MIC: 0.6525 µg/mL) and E. faecalis-NA (MIC: 0.3262 µg/mL). Thereby, C. bipinnatus EO did not show significant antibiotic resistance modulating activity. In conclusion, L. graveolens and A. ludoviciana EOs showed antibacterial activity and the greatest potential in inhibiting bacterial resistance to antibiotics. The dual activity of these EOs makes them a promising adjuvant in the treatment of diseases caused by multidrug-resistant pathogenic bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.